T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241512106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Marc Gutierrez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Leukemia, Prolymphocytic, T-Cell, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, R.A.W..
Abstract (Originalsprache)
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells. Most patients with T-PLL present with lymphocytosis, anemia, thrombocytopenia, and hepatosplenomegaly. Correct identification of T-PLL is essential because treatment for this disease is distinct from that of other T-cell neoplasms. In 2019, the T-PLL International Study Group (TPLL-ISG) established criteria for the diagnosis, staging, and assessment of response to treatment of T-PLL with the goal of harmonizing research efforts and supporting clinical decision-making. T-PLL pathogenesis is commonly driven by T-cell leukemia 1 (TCL1) overexpression and ATM loss, genetic alterations that are incorporated into the TPLL-ISG diagnostic criteria. The cooperativity between TCL1 family members and ATM is seemingly unique to T-PLL across the spectrum of T-cell neoplasms. The role of the T-cell receptor, its downstream kinases, and JAK/STAT signaling are also emerging themes in disease pathogenesis and have obvious therapeutic implications. Despite improved understanding of disease pathogenesis, alemtuzumab remains the frontline therapy in the treatment of naïve patients with indications for treatment given its high response rate. Unfortunately, the responses achieved are rarely durable, and the majority of patients are not candidates for consolidation with hematopoietic stem cell transplantation. Improved understanding of T-PLL pathogenesis has unveiled novel therapeutic vulnerabilities that may change the natural history of this lymphoproliferative neoplasm and will be the focus of this concise review.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Pathology, University of Illinois Chicago, Chicago, IL 60607, USA.
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 60607, USA.
ORCID-Profile: Marc Gutierrez, Carlos Murga-Zamalloa, Ryan Wilcox
Förderung
- NCI NIH HHS
- NIH HHS
- R.A.W.
Zitieren
APA
Gutierrez, M., Bladek, P., Goksu, B., Murga-Zamalloa, C., Bixby, D., & Wilcox, R. (2023). T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512106
Vancouver
Gutierrez M, Bladek P, Goksu B, Murga-Zamalloa C, Bixby D, Wilcox R. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512106
BibTeX
@article{Gutierrez2023,
author = {Gutierrez, Marc and Bladek, Patrick and Goksu, Busra and Murga-Zamalloa, Carlos and Bixby, Dale and Wilcox, Ryan},
title = {T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241512106}
}
EUVIMED